Medical Forum / Diseases and Disorders / Alzheimer's / April 2005
Cholesterol drugs and Alzheimers??
|
|
Thread rating:  |
genileuqcaj@aol.com - 21 Apr 2005 05:15 GMT Are there any scientific studies that link cholesterol drugs (Lipitor, Zocor, ect) as a cause of Alzheimers? My mother is taking Lipitor. My father seems to think it is the reason for her dementia. Mom takes several medications for various conditions, and her medications are covered by her insurance. But my father is uncomfortable giving Mom any medicines, even though he knows what happens when she doesn't get one or more of her medicines. Dad seems to think everything can be cured with an herbal supplement, and receives several "alternative medicine" journals in the mail. (I'm not bashing alternative medicine as a whole. But the publications he receives can be very misleading....)
Any help would be appreciated!
Dr. Harman - 21 Apr 2005 14:47 GMT Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding.
Parvathy S, Ehrlich M, Pedrini S, Diaz N, Refolo L, Buxbaum JD, Bogush A, Petanceska S, Gandy S.
Farber Institute for Neurosciences of Thomas Jefferson University, Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania 19107, USA. samgandy@earthlink.net
Studies of metabolism of the Alzheimer amyloid precursor protein (APP) have focused much recent attention on the biology of juxta- and intra-membranous proteases. Release or 'shedding' of the large APP ectodomain can occur via one of two competing pathways, the alpha- and beta-secretase pathways, that are distinguished both by subcellular site of proteolysis and by site of cleavage within APP. The alpha-secretase pathway cleaves within the amyloidogenic Abeta domain of APP, precluding the formation of toxic amyloid aggregates. The relative utilization of the alpha- and beta-secretase pathways is controlled by the activation of certain protein phosphorylation signal transduction pathways including protein kinase C (PKC) and extracellular signal regulated protein kinase [ERK/mitogen-activated protein kinase (MAP kinase)], although the relevant substrates for phosphorylation remain obscure. Because of their apparent ability to decrease the risk for Alzheimer disease, the effects of statins (HMG CoA reductase inhibitors) on APP metabolism were studied. Statin treatment induced an APP processing phenocopy of PKC or ERK activation, raising the possibility that statin effects on APP processing might involve protein phosphorylation. In cultured neuroblastoma cells transfected with human Swedish mutant APP, atorvastatin stimulated the release of alpha-secretase-released, soluble APP (sAPPalpha). However, statin-induced stimulation of sAPPalpha release was not antagonized by inhibitors of either PKC or ERK, or by the co-expression of a dominant negative isoform of ERK (dnERK), indicating that PKC and ERK do not play key roles in mediating the effect of atorvastatin on sAPPalpha secretion. These results suggest that statins may regulate alpha-secretase activity either by altering the biophysical properties of plasma membranes or by modulating the function of as-yet unidentified protein kinases that respond to either cholesterol or to some intermediate in the cholesterol metabolic pathway. A 'phospho-proteomic' analysis of N2a cells with and without statin treatment was performed, revealing changes in the phosphorylation state of several protein kinases plausibly related to APP processing. A systematic evaluation of the possible role of these protein kinases in statin-regulated APP ectodomain shedding is underway.
Karen - 22 Apr 2005 03:02 GMT When my MIL was diagnosed, they discontinued Lipitor to make sure it wasn't causing Alzheimer's type symptoms but I can't cite any studies. We told Hubby's cardiologist about that and about our concern of drug interactions and he recommended Hubby use Benacol and see if it would work before trying any statins. Benacol is a butter substitute that tastes good and seems very expensive until you look at it in the same light as a drug. You have to get 1 tablespoon 3 x day and they have capsules if you aren't eating something you would butter (like chinese food). It work on Hubby and his cholesterol came down from 385 to under 200 (with no side effects). Apparently, it works so well the FDA was looking at controlling it awhile back (saw it in the paper) but I think they decided not to.
It might be worth a monitored try. And yes, alternative medicine can be good or a crock and it's hard for many people to discern which.
Karen
> Are there any scientific studies that link cholesterol drugs (Lipitor, > Zocor, ect) as a cause of Alzheimers? My mother is taking Lipitor. My [quoted text clipped - 9 lines] > > Any help would be appreciated! Sharon Hope - 22 Apr 2005 04:10 GMT Absolutely Lipitor and the other cholesterol lowering statin drugs are known to cause memory loss much like Alzheimers - with symptoms close enough that many doctors are confused into thinking it is Alzheimers.
Get in contact with the UCSD Statin Study, a National Institutes of Health (NIH) funded study immediately. http://medicine.ucsd.edu/statin/contactinfo.html
See also Dr. Graveline's website for his book "Lipitor, Thief of Memory," and his new book, "Statin Drugs Side Effects." http://www.spacedoc.net/
Do not delay, get the information to her doctor, and if the doctor will not listen, find a different doctor who will. It can take many months to years to recover from statin cognitive damage.
My own husband took Lipitor 10 mg for 4 years, and developed all 3 of the most common serious side effects: Cognitive damage (Memory loss, and transient global amnesia and aphasia), muscle pain, and peripheral neuropathy. He was in his mid-50's, a successful CEO, until the Lipitor damage - his short-term memory loss was so bad that he measured below the 1 percentile in Neuropsych testing. He has been in cognitive rehabilitation therapy for 3 years off the Lipitor and has improved, but not fully recovered yet.
Statin adverse effects are documented, and the serious damage can be preventable - if doctors would only monitor for them. Typically, they not only do not monitor for statin memory loss, they deny it, delaying the remedy and deepening the damage.
Be certain the doctor files an adverse effects report with the FDA, and fills in the questionnaire for the Statin Study. It is just wrong that a patient be harmed to the degree that this degree of memory loss is obvious to the family, and they need to learn about it on an internet news group.
More info to take to the doctor: Statin Adverse Effects FAQ: MEMORY LOSS & STATINS, AMNESIA & STATINS
To my physician,
I believe that my symptoms may be due to the adverse effects associated with cholesterol-lowering statin drugs. I need your help to understand the cause of my symptoms, treatment options, and the prognosis for my recovery.
Please review the references below, published medical studies that show similar problems associated with statin drugs. These are made available via the National Institutes of Health (NIH, http://www.ncbi.nlm.nih.gov/Entrez/) library of biomedical journal citations and other major repositories of medical research.
Also, I am respectfully requesting that you file an adverse effects report with the FDA (http://www.fda.gov/medwatch/how.htm), and that you please send a copy of the report to the to the NIH-funded Statin Study, attention: Dr. Beatrice Golomb, Principal Investigator. Statin Study website: http://medicine.ucsd.edu/statin/ Statin Study contact info: http://medicine.ucsd.edu/statin/contactinfo.html UCSD STATIN STUDY E-MAIL ADDRESS: statinstudy@ucsd.edu MAILING ADDRESS: UCSD Statin Study 9500 Gilman Dr. La Jolla, CA 92093-0995 PHONE NUMBER: (858) 558-4950
Thank you
MEMORY LOSS & STATINS, AMNESIA & STATINS
References (updated as of January 7, 2005):
Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults.Am J Med. 2004 Dec 1;117(11):823-9. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB.Center for Clinical Pharmacology, University of Pittsburgh, Pennsylvania 15260, USA. mfm10@pitt.edu"This study provides partial support for minor decrements in cognitive functioning with statins. Whether such effects have any long-term sequelae or occur with other cholesterol-lowering interventions is not known." This is the second of two studies by Muldoon, both showing measurable cognitive decline in statin groups after only 6 months, using Neuropsychological (NP) testing. Further, this study identifies the subset of NP tests that are "statin sensitive" in detecting the cognitive deficits. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=15589485
Effects of lovastatin on cognitive function and psychological well-being.
Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, Manuck SB. After 6 months, 100% of the patients on placeboes showed a measurable increase in cognitive function, while the statin patients showed a measurable decrease in cognitive function in some areas. Am J Med. 2000 May;108(7):538-46. PMID: 10806282 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1 0806282&dopt=Abstract
Cognitive impairment associated with atorvastatin and simvastatin.King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW.Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA. dking@pharmacy.umsmed.eduPharmacotherapy. 2003 Dec;23(12):1663-7. "we report two women who experienced significant cognitive impairment temporally related to statin therapy. One woman took atorvastatin, and the other first took atorvastatin, then was rechallenged with simvastatin. Clinicians should be aware of cognitive impairment and dementia as potential adverse effects associated with statin therapy." PMID: 14695047 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=14695047
"DRUGS THAT MAKE YOU FORGET" Australian Adverse Drug Reactions Bulletin (Australia's equivalent to the FDA) Volume 17, Number 3, August 1998, section 3, page 3 Simvastatn is listed under "DRUGS THAT MAKE YOU FORGET" Recognizing the 14 reports of Amnesia under that drug, .8% of the total adverse effects for that drug. www.health.gov.au/tga/docs/pdf/aadrbltn/aadr9808.pdf
Statin-associated memory loss: analysis of 60 case reports and review of the literature. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Drug Information Service, Duke University Medical Center, Durham, North Carolina 27710, USA. Pharmacotherapy. 2003 Jul;23(7):871-80.
This study searched the MedWatch drug surveillance system of the Food and Drug Administration (FDA) from November 1997-February 2002 for reports of statin-associated memory loss. They also reviewed the published literature. References from the study are good for follow-up research.
Abstract: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1 2885101&dopt=Abstract
Full Study Text free on Medscape:
http://www.medscape.com/viewarticle/458867
The Role of Lipid-Lowering Drugs in Cognitive Function: A Meta-Analysis of Observational Studies
from Pharmacotherapy Posted 06/30/2003
Mahyar Etminan, Pharm.D., Sudeep Gill, M.D., FRCPC, Ali Samii, M.D., FRCPC
Although this study does bring the cognitive issues to light, it is a very poor study. The authors left out the pivotal study by Dr. Muldoon, that showed 100% of statin users had a measurable loss of cognitive ability after 6 months, while 100% of the placebo group improved their scores.
Abstract:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1 2820814&dopt=Abstract
Full Study Text free on Medscape:
http://www.medscape.com/viewarticle/456866
Simvastatin-Associated Memory Loss Amanda Orsi, Pharm.D., Olga Sherman, Pharm.D., and Zegga Woldeselassie, Pharm.D., Abstract: The statins are widely used to treat dyslipidemias. They are generally associated with mild adverse effects, but rarely, more serious reactions may occur. A 51-year-old man experienced delayed-onset, progressive memory loss while receiving simvastatin for hypercholesterolemia. His therapy was switched to pravastatin, and memory loss resolved gradually over the next month, with no recurrence of the adverse effect. from Pharmacotherapy Posted 06/01/2001 Page 1 of 3: http://www.medscape.com/viewarticle/409738?WebLogicSession=PXke2H8h99pyNVSCajAh5 clptzOAHJSZuNBobSwWmi9veWjdJ2A3%7C-1468812056489609316/184161392/6/7001/7001/700 2/7002/7001/-1 full printable version: http://www.medscape.com/viewarticle/409738_print
ADR of the Month September 2001 Vol. 6 No. 9 EDITORS Michelle W. McCarthy, Pharm.D. Anne E. Hendrick, Pharm.D.
University of Virginia Health System Department of Pharmacy Services Drug Information Center PO Box 800674 Charlottesville, VA 22908-0674 http://hsc.virginia.edu/pharmacy-services/Newsletters/ADR%20of%20the%20Month/ADR Month%209-01htm.html
Do HMG-CoA reductase inhibitors impair memory? The Tablet, a general member benefit published by the British Columbia Pharmacy Association, September 2001, Volume 10 no 8. Excerpt: Do HMG-CoA reductase inhibitors impair memory? After taking simvastatin for a year, a 51-year-old patient developed short term memory loss, to the extent of being unable to complete his sentences because he would forget what he was going to say. The drug was discontinued, replaced by pravastatin, and within one month his memory returned.14 In a separate case, a 67-year-old woman developed impaired short-term memory, altered mood, social impairment, cognitive impairment and dementia after one year of atorvastatin therapy. When atorvastatin was discontinued, her memory, mood and cognition improved completely.15 Memory impairment in a patient receiving atorvastatin has been reported to the BC Regional ADR Centre. REFERENCES: 14. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. 15. King DS, Jones DW, Wofford MR et al. First report of cognitive impairment in an elderly patient: case report. Pharmacotherapy 2001 Mar; 21: 371.
http://www.bcpharmacy.ca/publications/thetablet/pdf_version/BCPhA_Tablet-Sep2001.pdf See page 11 of 16:
AMNESIA & STATINS
Lipitor, Thief of Memory
Dr. Duane Graveline, retired family MD, USAF Flight Surgeon, researcher in space medicine and US Astronaut, who suffered adverse effects from Lipitor. The book is available through Amazon.com. Dr. Graveline maintains several websites and is working on a second book about statin drug side effects: www.spacedoc.net (you can start here and read about his life and his books) http://www.spacedoc.net/lipitor_thief_of_memory.html http://www.spacedoc.net/lipitor.htm http://www.spacedoc.net/statin_dialogues.htm
Australian Adverse Drug Reactions Bulletin (Australia's equivalent to the FDA) Volume 17, Number 3, August 1998, section 3, page 3 Simvastatn is listed under "DRUGS THAT MAKE YOU FORGET" Recognizing the 14 reports of Amnesia under that drug, .8% of the total adverse effects for that drug. www.health.gov.au/tga/docs/pdf/aadrbltn/aadr9808.pdf
===========
Please see also:
Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins.Am J Med Genet. 2004 Dec 15;131A(3):287-98. Edison RJ, Muenke M.Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda,Maryland 20892-3717, USA."The cholesterol-lowering "statin" drugs are contraindicated in pregnancy, but few data exist on their safety in human gestation. We reviewed case reports for patterns suggesting drug-related effects on prenatal development and considered a variety of mechanisms by which such effects, if confirmed, might occur. This uncontrolled case series included all FDA reports of statin exposures during gestation, as well as others from the literature and from manufacturers. Exposures and outcomes were reviewed and were tabulated by individual drug. Age-specific rates of exposure to each drug among women of child-bearing age were estimated. Of 214 ascertained pregnancy exposures, 70 evaluable reports remained after excluding uninformative cases. Among 31 adverse outcomes were 22 cases with structural defects, 4 cases of intrauterine growth restriction, and 5 cases of fetal demise. There were two principal categories of recurrent structural defects: cerivastatin and lovastatin were a_ssociated with four reports of severe midline CNS defects; simvastatin, lovastatin, and atorvastatin were all a_ssociated with reports of limb deficiencies, including two similar complex lower limb defects reported following simvastatin exposure. There were also two cases of VACTERL a_ssociation among the limb deficiency cases. All adverse outcomes were reported following exposure to cerivastatin, simvastatin, lovastatin, or atorvastatin, which are lipophilic and equilibrate between maternal and embryonic compartments. None were reported following exposure to pravastatin, which is minimally present in the embryo. Statins reaching the embryo may down-regulate biosynthesis of cholesterol as well as many important metabolic intermediates, and may have secondary effects on sterol-dependent morphogens such as Sonic Hedgehog. The reported cases display patterns consistent with dysfunction of cholesterol biosynthesis and Sonic Hedgehog activity. Controlled studies are needed to investigate the teratogenicity of individual drugs in this cla_ss."PMID: 15546153 [PubMed - in process]
Statins and risk of polyneuropathy, A case-control study D. Gaist, MD, PhD; U. Jeppesen, MD, PhD; M. Andersen, MD, PhD; L.A. García Rodríguez, MD, MSc; J. Hallas, MD, PhD; and S.H. Sindrup, MD, PhD http://213.4.18.135/87.pdf full text
Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. von Keutz E, Schluter G. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9 737641&dopt=Abstract Institute of Toxicology, PH-Product Development, Bayer AG, Wuppertal, Germany Am J Cardiol. 1998 Aug 27;82(4B):11J-17J. PMID: 9737641 "In dogs, the species most sensitive to statins, cerivastatin caused erosions and hemorrhages in the gastrointestinal tract, bleeding in the brain stem with fibroid degeneration of vessel walls in the choroid plexus, and lens opacity."
Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8 864188&dopt=Abstract Walsh KM, Albassam MA, Clarke DE. Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA. "The toxicity of atorvastatin (AT), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMG), was evaluated in beagle dogs. hemorrhage in gallbladder and brain, demyelination of optic nerve, and skeletal muscle necrosis"
Finally, on memory loss and statins: Sworn testimony from the Baycol trial in Corpus Christi, Texas. From the transcript of the AM Session on 03-05-03, in the case Hollis Haltom Vs. Bayer Corporation. Testifying under oath,., in response to the plaintiff's attorney's question, "What is your current position at Bayer?", LAWRENCE POSNER, M.D of BAYER stated: "I'm the -- currently I'm the head of worldwide regulatory affairs for our prescription drug business, which means I have responsibility in somewhere between 60 and 100 countries where we sell products for registrations, compliance, things of that nature." Excerpts from the trial transcript follow, with the Q indicating counsel's Question, and the A indicating Dr. Posner's Answer: Q. So there are some concerns addressed here back in 1995 about testing up to .8. And do you know what the nature of the concern was? A. Yes. It was related to a side effect that occurred in the brain. Q. Of what kind of animal? A. It occurred in the brain of dogs. Q. Okay. So there was a side effect that occurred in dogs, and then there was a concern about whether you wanted to go forward and test at this higher dose level in human beings, given what you had learned about the dogs, right? A. That's correct. Q. Okay. Now, did you just say, well, let's forget about these concerns and we'll go ahead and put .8 on the market anyway, or did you do some further analysis that was not mentioned the other day? A. Yes. The authors of this had -- they had two concerns. One concern was the toxicity that they found in the brain of dogs. But the other was that they had no way to identify this and who might be at risk before it happened. So there was no way to detect that someone was at risk for this side effect. [skip some testimony on other topics] Q. Do you remember in one kind of animal there had been some studies done that there could be a particular kind of problem with one kind of animal? A. Oh, yeah. Yes, from the -- that's correct, from the toxicology studies. Q. Okay. And were you able to demonstrate to your own satisfaction, to SmithKline's satisfaction, to the FDA's satisfaction, that that particular problem that showed up with that kind of animal is not something that happens in human beings? A. Yes. We did it -- we did it by explaining the toxicology data. We also explained it on the basis of kinetic data. That actually at the higher levels of drug, what happens is a certain amount of drug is bound to proteins in the body that circulate; and therefore, is not -- cannot cause side effects. And actually, a much smaller proportion of the drug is free. And that what you corrected for that, you actually found out that the margins of safety were in fact greater than you would predict just from the animal data. Q. And as you move forward then and got approval and sold Baycol from 1997 through 2001, did that problem that had shown up with that one kind of animal ever become a problem with human beings? A. It was actually shown with other statins as well. It wasn't unique to cerivastatin. It was a problem -- it was identified early on with lovastatin and some of the others. In fact, for none of the statins did it ever predict for any clinical problem or toxicity. Q. So these animals would have that same problem regardless of which statin -- or at least with other statins? A. Certainly with lovastatin it was true. Q. But when it came time to human beings, that just wasn't something that happened to human beings? A. And I think today no one pays much attention to it.
Statin Adverse Effects FAQ: NERVE DAMAGE & STATINS
References (updated as of January 7, 2005):
Statin-associated peripheral neuropathy: review of the literature.
Chong PH, Boskovich A, Stevkovic N, Bartt RE. Pharmacotherapy. 2004 Sep;24(9):1194-203. Review. PMID: 15460180 [PubMed - indexed for MEDLINE]http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=15460180"Based on epidemiologic studies as well as case reports, a risk of peripheral neuropathy associated with statin use may exist; however, the risk appears to be minimal. On the other hand, the benefits of statins are firmly established. These findings should alert prescribers to a potential risk of peripheral neuropathy in patients receiving any of the statins; that is, statins should be considered the cause of peripheral neuropathy when other etiologies have been excluded." Disorder resembling Guillain-Barre syndrome on initiation of statin therapy.Rajabally YA, Varakantam V, Abbott RJ. Muscle Nerve. 2004 Nov;30(5):663-6. PMID: 15389662 [PubMed - indexed for MEDLINE]http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=15389662"We report a disorder resembling Guillain-Barre syndrome, occurring on initiation of simvastatin, in a 58-year-old man, who had experienced a similar but milder episode after starting pravastatin 6 months earlier. This case suggests that acute polyradiculoneuropathy may represent a rare but serious side-effect of statin treatment. It also raises the issue of the pathophysiology of acute neuropathy on statin exposure, with a hypersensitivity reaction resulting in an immune-mediated process being possible instead of the hypothesized mitochondrial dysfunction in chronic cases." Simvastatin-induced mononeuropathy multiplex: case report.Scola RH, Trentin AP, Germiniani FM, Piovesan EJ, Werneck LC. Arq Neuropsiquiatr. 2004 Jun;62(2B):540-2. Epub 2004 Jul 20. PMID: 15273860 [PubMed - in process]http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=15273860"The association between the use of statins and neuromuscular disease is currently being intensely discussed. We relate a 63 years old man with possible case of statin-induced neuropathy in a patient with dislipidemia in use of simvastatina at high doses. The electrophysiologic studies disclosed findings compatible with mononeuropathy multiplex, suggested by clinical prescutation of asymmetrical numbness and weakness. More common causes of mononeuropathy multiplex were excluded and the patient improved after the discontinuation of the drug." Statins and risk of polyneuropathy, A case-control study D. Gaist, MD, PhD; U. Jeppesen, MD, PhD; M. Andersen, MD, PhD; L.A. García Rodríguez, MD, MSc; J. Hallas, MD, PhD; and S.H. Sindrup, MD, PhD http://213.4.18.135/87.pdf full text
From the abstract: "The authors verified a diagnosis of idiopathic polyneuropathy in 166 cases. The cases were classified as definite (35), probable (54), or possible (77). The odds ratio linking idiopathic polyneuropathy with statin use was 3.7 (95% CI 1.8 to 7.6) for all cases and 14.2 (5.3 to 38.0) for definite cases. The corresponding odds ratios in current users were 4.6 (2.1 to 10.0) for all cases and 16.1 (5.7 to 45.4) for definite cases. For patients treated with statins for 2 or more years the odds ratio of definite idiopathic polyneuropathy was 26.4 (7.8 to 45.4). CONCLUSIONS: Long-term exposure to statins may substantially increase the risk of polyneuropathy."
Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? David Gaist, Luis Alberto García Rodríguez · Consuelo Huerta · Jesper Hallas · Søren H. Sindrup http://213.4.18.135/75.pdf full text http://213.4.18.135/76.2.pdf full text http://213.4.18.135/87.pdf full text text
Pharmacodynamics: Statins and peripheral neuropathy U. Jeppesen (2), D. Gaist (1)(2), T. Smith (1), S. H. Sindrup (1)(2) (1) Department of Neurology, Odense University Hospital, DK-5000 Odense C, Denmark Tel.: +45-6541-2474, Fax: +45-6541-3389 (2) Department of Clinical Pharmacology Odense University, Odense, Denmark Received: 6 July 1998 / Accepted in revised form: 1 October 1998 Abstract Volume 54 Issue 11 (1999) pp 835-838 http://link.springer-ny.com/link/service/journals/00228/bibs/9054011/90540835.htm "Within the past 3 years seven cases of reversible peripheral neuropathy apparently caused by statins have been reported. Here we report seven additional cases associated with long-term statin therapy, in which other causes of neuropathy were thoroughly excluded. The neuropathy was in all cases axonal and with affection of both thick and thin nerve fibers. The symptoms of neuropathy persisted during an observation period lasting from 10 weeks to 1 year in four cases after statin treatment had been withdrawn. We suggest that long-term statin treatment may be associated with chronic peripheral neuropathy."
Association of HMG-CoA reductase inhibitors with neuropathy. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1 2549960&dopt=Abstract Ann Pharmacother. 2003 Feb;37(2):274-8. Backes JM, Howard PA. Department of Pharmacy Practice and Lipid, Atherosclerosis, Metabolic and LDL-Apheresis Clinic, University of Kansas Medical Center, Kansas City, KS 66160-7231, USA. jbackes@kumc.edu "Epidemiologic studies and case reports suggest an increased risk of peripheral neuropathy with statin drugs. The majority of cases were at least partially reversible with drug cessation." (emphasis added)
Selenoprotein synthesis and side-effects of statins.Moosmann B, Behl C. Lancet. 2004 Mar 13;363(9412):892-4. Review. PMID: 15031036 [PubMed - indexed for MEDLINE]http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=15031036
"We noted that the pattern of side-effects associated with statins resembles the pathology of selenium deficiency, and postulated that the mechanism lay in a well established, but often overlooked, biochemical pathway--the isopentenylation of selenocysteine-tRNA([Ser]Sec). A negative effect of statins on selenoprotein synthesis does seem to explain many of the enigmatic effects and side-effects of statins, in particular, statin-induced myopathy."
Statin therapy and small fibre neuropathy: a serial electrophysiological study. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1 2639733&dopt=Abstract Lo YL, Leoh TH, Loh LM, Tan CE. J Neurol Sci. 2003 Apr 15;208(1-2):105-8. Department of Neurology, Singapore General Hospital, Outram Road, Singapore. gnrlyl@sgh.com.sg Describes 3 patients who developed neuropathy after ONE MONTH of statin therapy. "One patient redeveloped small and large fibre neuropathy when the similar drug was readministered."
Peripheral Neuropathy and Lipid-Lowering Therapy Paul E. Ziajka, MD, PhD, and Tammy Wehmeier, RN, Orlando, Fla. Abstract: We report a case of peripheral neuropathy induced and excerbated by several commonly used HMG-CoA reductase inhibitors including lovastatin, simvastatin, pravastatin, and atorvastatin, and the vitamin niacin. A review of the literature shows similar cases with individual lipid-lowering drugs, but this case shows the cross-reactivity of the neuropathic process to different HMG-CoA reductase inhibitors, and is the first reported case of a peripheral neuropathy exacerbated by the use of niacin. http://www.sma.org/smj1998/julysmj98/ziajka.pdf
Peripheral neuropathy associated with simvastatin. Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. J Neurol Neurosurg Psychiatry. 1995 May;58(5):625-8. PMID: 7745415 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7 745415&dopt=Abstract
"Four patients are described who developed sensorimotor neuropathy while being treated with simvastatin and had complete or partial resolution of clinical abnormalities after withdrawal of treatment. In one case onset was within days of commencing treatment, but in two cases symptoms did not develop for two years. The electrophysiological and pathological features of the neuropathy were those of axonal degeneration. Clinical evidence of proximal and distal weakness and muscle fasciculations and persistent abnormalities of sensory conduction after recovery suggest the possibility of toxic damage to anterior horn cells and dorsal root ganglia. Thirty eight other cases with symptoms suggestive of peripheral neuropathy have been reported to the Australian Adverse Drug Reactions Advisory Committee, 22 of whom recovered after cessation of treatment; in five cases there was recurrence after re-exposure to the drug. Simvastatin should be considered among the causes of peripheral neuropathy, and the drug should be withdrawn if patients receiving it develop muscle weakness or sensory disturbances."
Lovastatin and peripheral neuropathy. Ahmad S. Am Heart J. 1995 Dec;130(6):1321. No abstract available. PMID: 7484806 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7 484806&dopt=Abstract
Vestibular vertigo and lovastatin therapy.
Ahmad S. South Med J. 1996 Feb;89(2):257-8. No abstract available. PMID: 8578368 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=8578368
HMG-CoA reductase inhibitor therapy and peripheral neuropathy.
Jacobs MB. Ann Intern Med. 1994 Jun 1;120(11):970. No abstract available. PMID: 8172444 [PubMed - indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8 172444&dopt=Abstract
Medication-induced peripheral neuropathy. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1 2507417&dopt=Abstract Curr Neurol Neurosci Rep. 2003 Jan;3(1):86-92. Review. Weimer LH. Neurological Institute of New York, 710 West 168th Street, Unit 55, New York, NY 10032, USA. Lhw1@columbia.edu PMID: 12507417 [PubMed - indexed for MEDLINE] "Although most cases demonstrate acute or subacute onset after exposure, recent experiences with statin drugs raise the possibility of occult toxic causes of chronic idiopathic neuropathy."
Neuropathy due to drugs.
Le Quesne PM.
In: Dyck PJ, Thomas PK, Griffin JW, et al, eds. Peripheral neuropathy. 3rd ed. Philadelphia: Saunders, 1993:1571-1581. (Book, no link)
> Are there any scientific studies that link cholesterol drugs (Lipitor, > Zocor, ect) as a cause of Alzheimers? My mother is taking Lipitor. My [quoted text clipped - 9 lines] > > Any help would be appreciated! Alan Meyer - 22 Apr 2005 19:08 GMT > Are there any scientific studies that link cholesterol drugs (Lipitor, > Zocor, ect) as a cause of Alzheimers? My mother is taking Lipitor. My [quoted text clipped - 9 lines] > > Any help would be appreciated! There is some evidence that statins LOWER the risk of Alzheimer's.
If you do a search in pubmed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
on the terms "statins" and "alzheimers" you'll see, as of today, 115 hits.
I looked at a number of them and found some claiming, based on retrospective study of patients, that statins lower the risk of Alzheimer's.
The theory behind all of this is still very much in a formative stage. Some scientists think that cholesterol in the brain is one of the causes or preconditions for Alzheimer's, and that lowering cholesterol reduces or delays the onset of the disease. Unfortunately however, it doesn't completely prevent the disease from occuring.
Alan
genileuqcaj@aol.com - 22 Apr 2005 20:28 GMT Reading the responses to my question, I have another question. Will dementia caused by a statin drug respond to a medicine for Alzheimers? Last summer we didn't reorder Mom's Exelon soon enough and ran out. My father wanted to see if there would be any change in Mom's behavior without the Exelon. Mom became combative about 3-4 times a week, and we were all miserable. Once she started back on her meds, she was her usual perky (but still confused) self.
Sharon Hope - 23 Apr 2005 02:23 GMT Typically, the treatment for statin memory loss is to stop the statin, and then supplement with 800-1,2000mg Coenzyme Q10 per day.
You need to ask the world expert, Dr. Golomb, the question on response to Exelon. I urge you to email or call the UCSD Statin Study, a National Institutes of Health (NIH) funded study immediately. http://medicine.ucsd.edu/statin/contactinfo.html.
Low cholesterol, by the way, is associated with violence and hostility, see the Frequently Asked Questions below:
Statin Adverse Effects FAQ: Low Cholesterol and Aggression, Violence, Crime, Depression, Suicide Attempts
Several published medical studies have found that low cholesterol levels have a direct correlation with mood and behavior, particularly aggression, violence, crime, depression, and/or suicide attempts.
Findings include:
· The authors concluded that, among non-African-American children, low total cholesterol is associated with school suspension or expulsion and that low total cholesterol may be a risk factor for aggression or a risk marker for other biologic variables that predispose to aggression.
· A significant increase in SERT (Serotonin transporter) activity was detected only during the first month of simvastatin therapy. This finding suggests that within this period some patients could be vulnerable to depression, violence, or suicide.
· This paper reviews early biological risk factors for violence. These factors include . low cholesterol. A biopsychosocial violence mode is proposed.
· The results suggest that total cholesterol level may be a useful biological marker for the risk of suicide in depression patients.
· The results indicated that medication-free schizophrenic patients have statistically significant lower serum cholesterol and leptin levels compared with controls and the difference is obvious in suicide attempters compared with non-suicide attempters and in violent attempters than non-violent attempters.
· Patients with a violent suicidal attempt have significantly lower cholesterol levels than patients with non-violent attempts and the control subjects. Our findings suggest that suicide attempts should not be considered a homogeneous group. They are consistent with the theory that low levels of cholesterol are associated with increased tendency for impulsive behavior and aggression and contribute to a more violent pattern of suicidal behavior.
· . The TC (low total serum cholesterol) level seems to be a peripheral marker with prognostic value among boys with conduct disorder and antisocial male offenders.
· Our results confirm previous reports of lower serum cholesterol in attempted suicide. They are also indicative of an increased noradrenaline turnover in subjects who attempt suicide, at least within 24 hours after the attempt. Whether this activation precedes or follows the attempt because of the specific stress, can not be answered at present.
· Low cholesterol may effect serotonergic neuronal activity and some types of 5-HT receptors, then may be related to violent behavior during sleep.
· These findings are consistent with the cholesterol-serotonin hypothesis and with the substantive literature linking both aggression and depression to depressed central serotonergic activity.
· Adjusting for other factors, low cholesterol is associated with increased subsequent criminal violence.
· These findings suggest the possibility that serum cholesterol levels may be positively associated with serotonergic receptor function. The existence of such an association may provide an explanation for reported increases in depression, suicide and violence in individuals with low or lowered cholesterol.
· Our results showed that low serum cholesterol level is associated with the violence of the suicide attempt and not with the suicide attempt itself. Further investigations are necessary to determine the usefulness of this easily accessible parameter as a potential risk indicator for violent acts such as violent suicidal behavior in susceptible individuals.
· Men with a lower cholesterol level (< or =4.5 mmol/liter) have a higher prevalence of depressive symptoms than those with a cholesterol level between 6 and 7 mmol/liter. These data may be important in the ongoing debate on the putative association between low cholesterol levels and violent death.
Some relatively recent full abstracts:
http://aje.oupjournals.org/cgi/content/abstract/161/7/691
Association of Serum Cholesterol and History of School Suspension among School-age Children and Adolescents in the United States Jian Zhang1, Matthew F. Muldoon2, Robert E. McKeown3 and Steven P. Cuffe4 1 Division of Health and Family Studies, Institute for Families in Society, University of South Carolina, Columbia, SC 2 Center for Clinical Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA 3 Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC 4 Department of Neuropsychiatry and Behavioral Science, Division of Child and Adolescent Psychiatry, University of South Carolina School of Medicine, Columbia, SC Correspondence to Dr. Jian Zhang, 4770 Buford Highway, MS K-24, Atlanta, GA 30341 (e-mail: bvw2@cdc.gov). The dietary guidelines developed for adults have been extended to children, but the role of serum cholesterol in the neurodevelopment of children is poorly understood. In the Third National Health and Nutrition Examination Survey (1988-1994), serum total cholesterol was measured in 4,852 children aged 6-16 years. Psychosocial development was evaluated by interviewing the mother regarding the child's history of school suspension or expulsion and difficulty in getting along with others. After adjustment for family socioeconomic status, maternal marital status and education, children's nutrition, and academic performance, the odds ratios of children with various concentrations of total cholesterol showed the children to be equally comfortable in their own peer subculture and not to be different in the proportion that had seen a mental health professional. However, non-African-American children with a serum total cholesterol concentration below the 25th percentile (<145 mg/dl) were almost threefold more likely to have been suspended or expelled from schools than their peers with total cholesterol at or above the 25th percentile (odds ratio = 2.96, 95% confidence interval: 1.55, 5.64). The authors concluded that, among non-African-American children, low total cholesterol is associated with school suspension or expulsion and that low total cholesterol may be a risk factor for aggression or a risk marker for other biologic variables that predispose to aggression. --- adolescent psychology; child psychology; cholesterol; juvenile delinquency; United States -------------------------------------------------------------------------------- Abbreviations: CI, confidence interval; DISC, Dietary Intervention Study in Children; NHANES III, Third National Health and Nutrition Examination Survey; STRIP, Special Turku Coronary Risk Factor Intervention Project; WRAT-R, Wide Range Achievement Test, Revised
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=15740995
Psychiatry Res. 2005 Feb 28;133(2-3):197-203.
Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Vevera J, Fisar Z, Kvasnicka T, Zdenek H, Starkova L, Ceska R, Papezova H. Psychiatric Clinic, First Faculty of Medicine of Charles University, Ke Karlovu 11, 120 00 Prague, Czech Republic; School of Public Health, University of California at Berkeley, Berkeley, CA, USA. A number of studies have reported an increased risk for violent deaths and depression in subjects with reduced serum cholesterol concentrations. Links with hypothesized impairment of serotonin neurotransmission have not been satisfactorily tested. In this investigation, the serum and membrane cholesterol, microviscosity of erythrocyte membranes, platelet serotonin uptake, and clinical parameters were determined during pharmacotherapy of 17 hypercholesterolemic patients. A significant decrease in serum cholesterol and a nonsignificant decrease in membrane cholesterol concentration were found after 2 months of simvastatin therapy. Serotonin transporter (SERT) activity was significantly increased following 1 month of simvastatin; the tendency to decrease the initial increase in SERT activity was evident following 2 months of therapy. Both membrane cholesterol and SERT activity returned to pre-treatment levels after more than 1 year of therapy. Microviscosity of plasma membranes, impulsivity, empathy, adventure, sensation seeking, and depressed mood were not markedly changed. These data indicate that long-term therapy has different effects on serotonin transmission from short-term (1- to 2-month) therapy. A significant increase in SERT activity was detected only during the first month of simvastatin therapy. This finding suggests that within this period some patients could be vulnerable to depression, violence, or suicide. PMID: 15740995 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=15680620
Int J Nurs Stud. 2005 Feb;42(2):229-41.
Biosocial bases of aggressive and violent behavior--implications for nursing studies. Liu J, Wuerker A. Social Science Research Institute, University of Southern California, Los Angeles, CA 90089-0375, USA. jianghol@usc.edu Although aggression and violence have been increasingly viewed as a major public health problem with a biological and health basis, it has been under-researched in the nursing and health context. This paper reviews early biological risk factors for violence. These factors include pregnancy/birth complications, fetal exposure to nicotine, alcohol, and drugs, low cholesterol, malnutrition, lead and manganese exposure, head injuries and brain dysfunction, low arousal, low serotonin, low cortisol, and high testosterone. A biopsychosocial violence mode is proposed. Finally, the paper argues that nursing is ideally placed to develop a new body of knowledge based on a biosocial perspective that can lead to more effective prevention programs for violence. PMID: 15680620 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=15306143
J Affect Disord. 2004 Aug;81(2):161-6.
Clinical application of low serum cholesterol as an indicator for suicide risk in major depression. Kim YK, Myint AM. Department of Psychiatry, Korea University College of Medicine, Seoul, South Korea. yongku@korea.ac.kr BACKGROUND: Serum total cholesterol is reported to be associated with suicidality and violence. We explored the clinical applicability of low serum total cholesterol as an indicator for suicide risk in major depression. METHOD: We measured the serum cholesterol levels in 149 major depressive disorder patients admitted to an emergency room following a suicide attempt, in 149 non-suicidal depressive controls, and in 251 normal controls. RESULTS: Significant differences in total serum cholesterol levels were observed between the suicide patients and non-suicide depression patients and between violent suicide patients and non-violent suicide patients when age, sex, BMI and total serum protein levels were controlled. The cutoff point of 180 mg/dl gave a high sensitivity (82%), and the cutoff point 150 mg/dl gave a high specificity (72%). These points can be used as discriminative cutoffs between suicidal and non-suicidal depressive patients. LIMITATIONS: A longitudinal study is necessary to confirm the clinical applicability of serum cholesterol as a predictive indicator of suicide risk in depression. CONCLUSION: The results suggest that total cholesterol level may be a useful biological marker for the risk of suicide in depression patients. PMID: 15306143 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=12890276
Acta Psychiatr Scand. 2003 Sep;108(3):208-14.
Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Departments of Psychiatry and Clinical Biochemistry, Firat University, School of Medicine, Elazig, Turkey. matmaca_p@yahoo.com OBJECTIVE: Previous studies demonstrate a relationship between lipid metabolism and suicide or impulsive-aggressive behaviours. Leptin seems to be related with lipid metabolism. Therefore, the aim was to measure total serum cholesterol and leptin levels in 16 medication-free schizophrenic patients with and without suicide attempts and in 16 healthy controls. METHOD: Subjects were assessed by using Impulsivity Rating (IRS) and Modified Overt Aggression Scale (MOAS). RESULTS: The patients had lower total cholesterol and leptin levels in serum compared with the controls. Significantly lower total cholesterol and leptin levels were observed in patients who had attempted suicide compared with those who had not. The levels were observed to be low in violent attempters when compared with non-violent attempters. MOAS and IRS scores were negatively correlated with both cholesterol or leptin levels in patients. CONCLUSION: The results indicated that medication-free schizophrenic patients have statistically significant lower serum cholesterol and leptin levels compared with controls and the difference is obvious in suicide attempters compared with non-suicide attempters and in violent attempters than non-violent attempters. PMID: 12890276 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=12880147
Clin Chem Lab Med. 2003 Jun;41(6):821-4.
Association between increased serum cholesterol and signs of depressive mood. Ledochowski M, Murr C, Sperner-Unterweger B, Neurauter G, Fuchs D. Department of Internal Medicine, Leopold-Franzens University, Innsbruck, Austria. Hypercholesterolemia is associated with an increased risk of atherosclerosis and coronary heart disease. Therefore, therapeutic lowering of cholesterol is an important preventive measure of cardiac morbidity and death. As one side effect, cholesterol-lowering drugs appear to increase the mortality due to suicides or violence, and low lipid concentrations were found to be associated with trait measures of depression. We compared serum cholesterol concentrations and the Beck Depression Rating Scale (Beck's score) in 604 otherwise healthy outpatients who visited the physician's office for a medical health check-up; 65.4% of individuals presented with serum cholesterol concentrations > or = 5.2 mmol/l (> 200 mg/dl) and 5.3% had elevated Beck's score (> 19), indicative for depression. Beck's score was higher in patients with cholesterol concentrations above the 75th percentile (= 6.2 mmol/l; U = 31221, p < 0.02, Mann-Whitney U-test), and Beck's score correlated with cholesterol concentrations and with age. Thus, in contrast to the widely accepted view, in our study, higher cholesterol concentrations were associated with signs of depressive mood. Hypercholesterolemia may not necessarily increase the risk of depressive mood, conversely, increased intake of fat and carbohydrates by individuals with depressive mood may increase cholesterol levels. PMID: 12880147 [PubMed - indexed for MEDLINE]
(SH: So, perhaps eating chocolate or other fats and carbohydrates is a natural way to recover from depression?)
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=12648892
Eur Psychiatry. 2003 Feb;18(1):23-7.
Cholesterol concentrations in violent and non-violent women suicide attempters. Vevera J, Zukov I, Morcinek T, Papezova H. Psychiatric Clinic, 1st Medical Faculty, Charles University of Prague, Prague, Czech Republic. j_vevera@hotmail.com The aim of this study was to evaluate whether women with a history of violent suicide attempts have lower serum cholesterol concentrations than those who attempted suicide by non-violent methods. Our retrospective study used a case-control design to compare serum total cholesterol concentration, hematocrit, red blood cell count and body mass index (BMI) in women with a history of violent (n = 19) or non-violent (n = 51) suicide attempts and of non-suicidal controls (n = 70) matched by diagnosis and age. Analysis of covariance (ANCOVA) with age as the covariate was used to analyze differences in cholesterol levels in groups according to violence. Violence was found to be a significant factor (P = 0.016). Using the Scheffe test, a significant difference (P = 0.011) was revealed between the group of violent and non-violent suicide attempters and between the violent suicide attempters and the control group. Patients with a violent suicidal attempt have significantly lower cholesterol levels than patients with non-violent attempts and the control subjects. Our findings suggest that suicide attempts should not be considered a homogeneous group. They are consistent with the theory that low levels of cholesterol are associated with increased tendency for impulsive behavior and aggression and contribute to a more violent pattern of suicidal behavior. PMID: 12648892 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=12056583
Eur Arch Psychiatry Clin Neurosci. 2002 Feb;252(1):8-11.
Total serum cholesterol level, violent criminal offences, suicidal behavior, mortality and the appearance of conduct disorder in Finnish male criminal offenders with antisocial personality disorder. Repo-Tiihonen E, Halonen P, Tiihonen J, Virkkunen M. Department of Forensic Psychiatry, University of Kuopio, Niuvanniemi Hospital, Finland. eila.tiihonen@niuva.fi Associations between low total serum cholesterol (TC) levels and antisocial personality disorder (ASPD), violent and suicidal behavior have been found. We investigated the associations between TC levels, violent and suicidal behavior, age of onset of the conduct disorder (CD) and the age of death among 250 Finnish male criminal offenders with ASPD. The CD had begun before the age of 10 two times more often in non-violent criminal offenders who had lower than median TC levels. The violent criminal offenders having lower than median TC levels were seven times more likely to die before the median age of death in the study material. The violent offenders having lower than median TC levels were eight times more likely to die of unnatural causes. The mean TC level of these male offenders with ASPD was lower than that of the general Finnish male population. Low TC levels are associated with childhood onset type of the CD, and premature and unnatural mortality among male offenders with ASPD. The TC level seems to be a peripheral marker with prognostic value among boys with conduct disorder and antisocial male offenders. PMID: 12056583 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=12056581
Eur Arch Psychiatry Clin Neurosci. 2002 Feb;252(1):38-43.
Biogenic amine turnover and serum cholesterol in suicide attempt. Tripodianakis J, Markianos M, Sarantidis D, Agouridaki M. Evangelismos General Hospital, Psychiatric Department, Athens, Greece. tripodianakis@hotmail.com The investigation of biological correlates of suicidal behavior is important in searching for possible changes in neuronal systems activity related to that behavior, so that pharmacological interventions may be proposed, especially in high-risk subjects. In a sample of 111 subjects admitted in a general hospital after suicide attempt, we studied the turnover of neurotransmitters by measuring the urinary output of the main metabolites of serotonin, dopamine and noradrenaline (5-HIAA, HVA, MHPG respectively), as well as serum cholesterol, and compared them to those of a group of 62 healthy controls. Venous blood samples and urine samples were collected within 24 hours of admission. Psychiatric diagnosis was made according to DSM-IIIR criteria and assessment of suicide intent with Beck's Suicidal Intent Scale (SIS). Fifty-four (54) subjects received the diagnosis of adjustment disorder, 25 of depression, 16 of schizophrenia and 16 of personality disorder. Fourteen subjects (14) had employed a violent mode of attempt. Urinary MHPG was found significantly higher in all diagnostic groups compared to controls. No difference was found concerning the excretion of HVA and 5-HIAA. Serum total cholesterol was found significantly lower both in violent and non-violent attempters compared to controls after correcting for age. No difference in serum cholesterol or MHPG was found between violent and non-violent attempts. Serum cholesterol and MHPG correlated negatively, while the correlations between cholesterol and 5-HIAA or HVA were not significant. Our results confirm previous reports of lower serum cholesterol in attempted suicide. They are also indicative of an increased noradrenaline turnover in subjects who attempt suicide, at least within 24 hours after the attempt. Whether this activation precedes or follows the attempt because of the specific stress, can not be answered at present. PMID: 12056581 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=11952924
Psychiatry Clin Neurosci. 2002 Apr;56(2):195-8.
Sleep-related violence and low serum cholesterol: a preliminary study. Agargun MY, Sekeroglu MR, Kara H, Ozer OA, Tombul T, Kiran U, Selvi Y. Department of Psychiatry, Yuzuncu Yil University School of Medicine, Van, Turkey. mehmetyucel@turk.net To examine whether there is a relationship between serum cholesterol level and sleep-related violence, we evaluated 15 patients with violent behavior during sleep (VBS) and 15 normal control subjects. The patient and control groups were matched for sex, age, and weight. There were 13 women and two men in each group. The patients with VBS had lower serum total cholesterol, triglyceride, and low-density lipoprotein levels than the healthy subjects. Low cholesterol may effect serotonergic neuronal activity and some types of 5-HT receptors, then may be related to violent behavior during sleep. PMID: 11952924 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=11199085
J Behav Med. 2000 Dec;23(6):519-29.
Serum cholesterol concentrations and mood states in violent psychiatric patients: an experience sampling study. Hillbrand M, Waite BM, Miller DS, Spitz RT, Lingswiler VM. Connecticut Valley Hospital, Whiting Forensic Division, P.O. Box 70, Middletown, Connecticut 06457, USA. hillbrandm@ccsu.edu The well-documented negative association between serum cholesterol and aggressive behavior has led Kaplan to propose a cholesterol-serotonin hypothesis of aggression. According to this hypothesis, low dietary cholesterol intake leads to depressed central serotonergic activity, which itself has been reported in numerous studies of violent individuals. In the present study, 25 violent psychiatric patients participated in a microbehavioral experience sampling procedure to examine differences in self-reports of affective and cognitive experiences as a function of serum cholesterol concentrations. For 7 days, they wore signaling devices that emitted an average of seven signals a day. Following each signal, patients filled out a mood questionnaire. Total serum cholesterol (TSC) concentration was positively associated with measures of affect, cognitive efficiency, activation, and sociability, suggesting a link between low TSC and dysphoria. These findings are consistent with the cholesterol-serotonin hypothesis and with the substantive literature linking both aggression and depression to depressed central serotonergic activity. PMID: 11199085 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=11104842
J Psychiatr Res. 2000 Jul-Oct;34(4-5):301-9.
Low cholesterol and violent crime. Golomb BA, Stattin H, Mednick S. Department of Medicine, University of California, Los Angeles, CA 92093-0995, USA. bgolomb@ucsd.edu BACKGROUND: Community cohort studies and meta-analyses of randomized trials have shown a relation between low or lowered cholesterol and death by violence (homicide, suicide, accident); in primates, cholesterol reduction has been linked to increased behavioral acts of aggression (Kaplan J, Manuck S. The effects of fat and cholesterol on aggressive behaviour in monkeys. Psychosom. Med 1990;52:226-7; Kaplan J, Shively C, Fontenot D, Morgan T, Howell S, Manuck S et al. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behaviour in monkeys. Psychosom. Med 1994;56:479-84.). In this study we test for the first time whether cholesterol level is related to commission of violent crimes against others in a large community cohort. METHODS: We merged one-time cholesterol measurements on 79,777 subjects enrolled in a health screening project in Varmland, Sweden with subsequent police records for arrests for violent crimes in men and women aged 24-70 at enrollment; and with information on covariates. We performed a nested case control comparison of cholesterol in violent criminals - defined as those with two or more crimes of violence against others - to cholesterol in nonoffenders matched on age, enrollment year, sex, education and alcohol, using variable-ratio matching, with a nonparametric sign test. RESULTS: One hundred individuals met criteria for criminal violence. Low cholesterol (below the median) was strongly associated with criminal violence in unadjusted analysis (Men: risk ratio 1.94, P=0.002; all subjects risk ratio 2.32, P<0.001). Age emerged as a strong confounder. Adjusting for covariates using a matching procedure, violent criminals had significantly lower cholesterol than others identical in age, sex, alcohol indices and education, using a nonparametric sign test (P=0.012 all subjects; P=0.035 men). CONCLUSIONS: Adjusting for other factors, low cholesterol is associated with increased subsequent criminal violence. PMID: 11104842 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=11063789
Psychiatry Res. 2000 Oct 30;96(2):167-73.
Relationship between serum cholesterol levels and meta-chlorophenylpiperazine-induced cortisol responses in healthy men and women. Terao T, Nakamura J, Yoshimura R, Ohmori O, Takahashi N, Kojima H, Soeda S, Shinkai T, Nakano H, Okuno T. Department of Psychiatry, University of Occupational and Environmental Health, School of Medicine, Yahatanishi-ku, 807-8555, Kitakyushu, Japan. t-terao@med.uoeh-u.ac.jp We investigated the effect of cholesterol on serotonergic receptor function in 20 healthy male and 10 healthy female subjects using cortisol responses to meta-chlorophenylpiperazine (m-CPP) neuroendocrine challenge tests. M-CPP, a metabolite of the antidepressant trazodone, has been widely used in psychopharmacology research as a probe of serotonin function. In the human brain, m-CPP binds both to various serotonergic receptors, mainly 5-HT(2C), and to alpha(2)-adrenoceptors. After an overnight fast, the subjects received m-CPP (0.5 mg/kg) or identical placebo capsules orally in a randomized, double blind, crossover design. Blood was obtained for measurement of cholesterol and cortisol. In some analyses, especially in males, there were significant positive correlations between serum cholesterol levels and cortisol responses. These findings suggest the possibility that serum cholesterol levels may be positively associated with serotonergic receptor function. The existence of such an association may provide an explanation for reported increases in depression, suicide and violence in individuals with low or lowered cholesterol. Publication Types:
· Clinical Trial
· Randomized Controlled Trial
PMID: 11063789 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=10963796
Psychiatry Res. 2000 Aug 21;95(2):103-8.
Low serum cholesterol in violent but not in non-violent suicide attempters. Alvarez JC, Cremniter D, Gluck N, Quintin P, Leboyer M, Berlin I, Therond P, Spreux-Varoquaux O. Faculte de Medecine Paris-Ouest et Laboratoire de Biochimie, Hopital R. Poincare, AP-HP, 104 Bvd R. Poincare, 92380 Garches, France. jean-claude.alvarez@rcp.ap-hop-paris.fr Many previous studies have suggested that low or lowered serum cholesterol levels may increase the risk of mortality not due to somatic disease: principally, suicide and violent death. Because violent death is rare, some studies have investigated afterwards the relation between cholesterol levels and either suicide attempts in psychiatric populations or violence in criminally violent populations. However, none of these studies have compared cholesterol levels in violent and non-violent suicide attempters. The blood of 25 consecutive drug-free patients following a violent suicide attempt and of 27 patients following a non-violent suicide attempt by drug overdose was drawn in the 24 h following admission. Patients with a diagnosis of alcohol abuse and with cholesterol-lowering therapy were excluded. Age, sex, body mass index, psychiatric diagnosis and the physical conditions of the suicide attempt were investigated. Thirty-two healthy subjects were used as a control group. There were no differences between the groups in age, frequency of psychiatric diagnoses or body mass index. There was more women in the group of non-violent suicide attempters than in that of violent suicide attempters (P<0.001). In analyses controlling for sex and age, the serum cholesterol concentration was 30% lower (F(2,82)=15.8; P<0.0001) in the group of violent suicide attempters (147+/-54 mg/dl) than in the group of non-violent suicide attempters (209+/-38 mg/dl) or control subjects (213+/-46 mg/dl). Our results showed that low serum cholesterol level is associated with the violence of the suicide attempt and not with the suicide attempt itself. Further investigations are necessary to determine the usefulness of this easily accessible parameter as a potential risk indicator for violent acts such as violent suicidal behavior in susceptible individuals. PMID: 10963796 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra ct&list_uids=10772398
Psychosom Med. 2000 Mar-Apr;62(2):205-11.
Higher prevalence of depressive symptoms in middle-aged men with low serum cholesterol levels. Steegmans PH, Hoes AW, Bak AA, van der Does E, Grobbee DE. Department of Epidemiology, Erasmus University Medical School, Rotterdam, The Netherlands. OBJECTIVE: Investigators from several studies have reported a positive relationship between low cholesterol levels and death due to violent causes (eg, suicide and accidents), possibly mediated by depressive symptoms, aggression or hostility, or impulsivity. We set out to establish whether middle-aged men with chronically low cholesterol levels (< or =4.5 mmol/liter) have a higher risk of having depressive symptoms, according to scores on the Beck Depression Inventory, compared with a reference group of men with cholesterol levels between 6 and 7 mmol/liter. A similar comparison was also made for measures of anger, hostility, and impulsivity. METHODS: Cholesterol measurements were obtained as part of a population-based cholesterol screening study in 1990-1991. These levels were remeasured in 1993-1994. Only those whose cholesterol level remained in the same range were included in the study. Depressive symptoms were assessed by using the Beck Depression Inventory; anger, by questionnaires based on the Spielberger Anger Expression Scale and State-Trait Anger Scale; hostility, by the Buss-Durkee Hostility Inventory; and impulsivity, by the Eysenck and Eysenck Impulsivity Questionnaire. RESULTS: Men with chronically low cholesterol levels showed a consistently higher risk of having depressive symptoms (Beck Depression Inventory score > or =15 or > or =17) than the reference group, even after adjusting for age, energy intake, alcohol use, and presence of chronic diseases. No differences in anger, hostility, and impulsivity were observed between the two groups. CONCLUSIONS: Men with a lower cholesterol level (< or =4.5 mmol/liter) have a higher prevalence of depressive symptoms than those with a cholesterol level between 6 and 7 mmol/liter. These data may be important in the ongoing debate on the putative association between low cholesterol levels and violent death. PMID: 10772398 [PubMed - indexed for MEDLINE]
==========================================================
The foregoing abstracts are of the more recent studies, but there are many more. A search of the National Institutes of Health (NIH) PubMed, using the search terms "cholesterol" + "violence" yields the following list, the overwhelming majority of which studies indicate a positive correlation between low cholesterol and violence or similar behaviors:
1: Vevera J, Fisar Z, Kvasnicka T, Zdenek H, Starkova L, Ceska R, Papezova H. Cholesterol-lowering therapy evokes time-limited changes in serotonergictransmission.Psychiatry Res. 2005 Feb 28;133(2-3):197-203. PMID: 15740995 [PubMed - in process] 2: Liu J, Wuerker A. Biosocial bases of aggressive and violent behavior--implications for nursingstudies.Int J Nurs Stud. 2005 Feb;42(2):229-41. PMID: 15680620 [PubMed - in process] 3: Kim YK, Myint AM. Clinical application of low serum cholesterol as an indicator for suicide riskin major depression.J Affect Disord. 2004 Aug;81(2):161-6. PMID: 15306143 [PubMed - indexed for MEDLINE] 4: Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and cholesterol levels in schizophrenic patients with and withoutsuicide attempts.Acta Psychiatr Scand. 2003 Sep;108(3):208-14. PMID: 12890276 [PubMed - indexed for MEDLINE] 5: Ledochowski M, Murr C, Sperner-Unterweger B, Neurauter G, Fuchs D. Association between increased serum cholesterol and signs of depressive mood.Clin Chem Lab Med. 2003 Jun;41(6):821-4. PMID: 12880147 [PubMed - indexed for MEDLINE] 6: Vevera J, Zukov I, Morcinek T, Papezova H. Cholesterol concentrations in violent and non-violent women suicide attempters.Eur Psychiatry. 2003 Feb;18(1):23-7. PMID: 12648892 [PubMed - indexed for MEDLINE] 7: Golaszewski T, Barr D, Pronk N. Development of assessment tools to measure organizational support for employeehealth.Am J Health Behav. 2003 Jan-Feb;27(1):43-54. PMID: 12500951 [PubMed - indexed for MEDLINE] 8: Tochigi M, Umekage T, Otani T, Kato T, Iwanami A, Asukai N, Sasaki T, KatoN. Serum cholesterol, uric acid and cholinesterase in victims of the Tokyo subwaysarin poisoning: a relation with post-traumatic stress disorder.Neurosci Res. 2002 Nov;44(3):267-72. PMID: 12413655 [PubMed - indexed for MEDLINE] 9: Cantor CH. An ecological perspective of cholesterol.Med J Aust. 2002 Jun 3;176(11):564. No abstract available. PMID: 12064996 [PubMed - indexed for MEDLINE] 10: Repo-Tiihonen E, Halonen P, Tiihonen J, Virkkunen M. Total serum cholesterol level, violent criminal offences, suicidal behavior,mortality and the appearance of conduct disorder in Finnish male criminaloffenders with antisocial personality disorder.Eur Arch Psychiatry Clin Neurosci. 2002 Feb;252(1):8-11. PMID: 12056583 [PubMed - indexed for MEDLINE] 11: Tripodianakis J, Markianos M, Sarantidis D, Agouridaki M. Biogenic amine turnover and serum cholesterol in suicide attempt.Eur Arch Psychiatry Clin Neurosci. 2002 Feb;252(1):38-43. PMID: 12056581 [PubMed - indexed for MEDLINE] 12: Agargun MY, Sekeroglu MR, Kara H, Ozer OA, Tombul T, Kiran U, Selvi Y. Sleep-related violence and low serum cholesterol: a preliminary study.Psychiatry Clin Neurosci. 2002 Apr;56(2):195-8. PMID: 11952924 [PubMed - indexed for MEDLINE] 13: Menotti A, Blackburn H, Kromhout D, Nissinen A, Adachi H, Lanti M. Cardiovascular risk factors as determinants of 25-year all-cause mortality inthe seven countries study.Eur J Epidemiol. 2001;17(4):337-46. PMID: 11767959 [PubMed - indexed for MEDLINE] 14: Huang TL. Serum cholesterol levels in mood disorders associated with physical violence orsuicide attempts in Taiwanese.Chang Gung Med J. 2001 Sep;24(9):563-8. PMID: 11725626 [PubMed - indexed for MEDLINE] 15: Terao T, Whale R. High serum cholesterol and suicide risk.Am J Psychiatry. 2001 May;158(5):824-5. No abstract available. PMID: 11329428 [PubMed - indexed for MEDLINE] 16: Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.Drugs. 2001;61(2):197-206. Review. PMID: 11270938 [PubMed - indexed for MEDLINE] 17: Hillbrand M, Waite BM, Miller DS, Spitz RT, Lingswiler VM. Serum cholesterol concentrations and mood states in violent psychiatricpatients: an experience sampling study.J Behav Med. 2000 Dec;23(6):519-29. PMID: 11199085 [PubMed - indexed for MEDLINE] 18: Manfredini R, Caracciolo S, Salmi R, Boari B, Tomelli A, Gallerani M. The association of low serum cholesterol with depression and suicidalbehaviours: new hypotheses for the missing link.J Int Med Res. 2000 Nov-Dec;28(6):247-57. Review. PMID: 11191718 [PubMed - indexed for MEDLINE] 19: McAllister M. Domestic violence: a life-span approach to assessment and intervention.Lippincotts Prim Care Pract. 2000 Mar-Apr;4(2):174-89; quiz 190-2. PMID: 11143628 [PubMed - indexed for MEDLINE] 20: Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH. Cholesterol reduction and non-illness mortality: meta-analysis of randomisedclinical trials.BMJ. 2001 Jan 6;322(7277):11-5. PMID: 11141142 [PubMed - indexed for MEDLINE] 21: Golomb BA, Stattin H, Mednick S. Low cholesterol and violent crime.J Psychiatr Res. 2000 Jul-Oct;34(4-5):301-9. PMID: 11104842 [PubMed - indexed for MEDLINE] 22: Stewart RA, Sharples KJ, North FM, Menkes DB, Baker J, Simes J. Long-term assessment of psychological well-being in a randomizedplacebo-controlled trial of cholesterol reduction with pravastatin. The LIPIDStudy Investigators.Arch Intern Med. 2000 Nov 13;160(20):3144-52. PMID: 11074745 [PubMed - indexed for MEDLINE] 23: Huang T, Wu S. Serum cholesterol levels in paranoid and non-paranoid schizophrenia associatedwith physical violence or suicide attempts in Taiwanese.Psychiatry Res. 2000 Oct 30;96(2):175-8. PMID: 11063790 [PubMed - indexed for MEDLINE] 24: Terao T, Nakamura J, Yoshimura R, Ohmori O, Takahashi N, Kojima H, Soeda S,Shinkai T, Nakano H, Okuno T. Relationship between serum cholesterol levels andmeta-chlorophenylpiperazine-induced cortisol responses in healthy men and women.Psychiatry Res. 2000 Oct 30;96(2):167-73. PMID: 11063789 [PubMed - indexed for MEDLINE] 25: Alvarez JC, Cremniter D, Gluck N, Quintin P, Leboyer M, Berlin I, TherondP, Spreux-Varoquaux O. Low serum cholesterol in violent but not in non-violent suicide attempters.Psychiatry Res. 2000 Aug 21;95(2):103-8. PMID: 10963796 [PubMed - indexed for MEDLINE] 26: Steegmans PH, Hoes AW, Bak AA, van der Does E, Grobbee DE. Higher prevalence of depressive symptoms in middle-aged men with low serumcholesterol levels.Psychosom Med. 2000 Mar-Apr;62(2):205-11. PMID: 10772398 [PubMed - indexed for MEDLINE] 27: Tanskanen A, Vartiainen E, Tuomilehto J, Viinamaki H, Lehtonen J, Puska P. High serum cholesterol and risk of suicide.Am J Psychiatry. 2000 Apr;157(4):648-50. PMID: 10739432 [PubMed - indexed for MEDLINE] 28: Seneviratne SL, Warnasooriya WM, Gunatilake SB, Fonseka MM, Gunawardena MK,de Silva HJ. Serum cholesterol concentrations in parasuicide.Ceylon Med J. 1999 Mar;44(1):11-3. PMID: 10643091 [PubMed - indexed for MEDLINE] 29: Hibbeln JR, Umhau JC, George DT, Shoaf SE, Linnoila M, Salem N Jr. Plasma total cholesterol concentrations do not predict cerebrospinal fluidneurotransmitter metabolites: implications for the biophysical role of highlyunsaturated fatty acids.Am J Clin Nutr. 2000 Jan;71(1 Suppl):331S-8S. PMID: 10617992 [PubMed - indexed for MEDLINE] 30: Steinert T, Woelfle M, Gebhardt RP. No correlation of serum cholesterol levels with measures of violence inpatients with schizophrenia and non-psychotic disorders.Eur Psychiatry. 1999 Oct;14(6):346-8. PMID: 10572367 [PubMed - indexed for MEDLINE] 31: Apter A, Laufer N, Bar-Sever M, Har-Even D, Ofek H, Weizman A. Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depressionin adolescent psychiatric inpatients.Biol Psychiatry. 1999 Aug 15;46(4):532-41. PMID: 10459404 [PubMed - indexed for MEDLINE] 32: Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V, Pajarinen J,Penttila A, Lalu KH, Mannikko A, Liesto KK, Koivula T, Karhunen PJ. Age-dependent association of apolipoprotein E genotype with coronary and aorticatherosclerosis in middle-aged men: an autopsy study.Circulation. 1999 Aug 10;100(6):608-13. PMID: 10441097 [PubMed - indexed for MEDLINE] 33: Alvarez JC, Cremniter D, Lesieur P, Gregoire A, Gilton A, Macquin-Mavier I,Jarreau C, Spreux-Varoquaux O. Low blood cholesterol and low platelet serotonin levels in violent suicideattempters.Biol Psychiatry. 1999 Apr 15;45(8):1066-9. PMID: 10386194 [PubMed - indexed for MEDLINE] 34: New AS, Sevin EM, Mitropoulou V, Reynolds D, Novotny SL, Callahan A,Trestman RL, Siever LJ. Serum cholesterol and impulsivity in personality disorders.Psychiatry Res. 1999 Feb 22;85(2):145-50. PMID: 10220005 [PubMed - indexed for MEDLINE] 35: Klein JD, Graff CA, Santelli JS, Hedberg VA, Allan MJ, Elster AB. Developing quality measures for adolescent care: validity of adolescents'self-reported receipt of preventive services.Health Serv Res. 1999 Apr;34(1 Pt 2):391-404. PMID: 10199683 [PubMed - indexed for MEDLINE] 36: Puska P, Vartiainen E, Tuomilehto J, Salomaa V, Nissinen A. Changes in premature deaths in Finland: successful long-term prevention ofcardiovascular diseases.Bull World Health Organ. 1998;76(4):419-25. PMID: 9803593 [PubMed - indexed for MEDLINE] 37: Weinberger RF. Cholesterol and violence: is there a connection?Ann Intern Med. 1998 Oct 15;129(8):669-70. No abstract available. PMID: 9786821 [PubMed - indexed for MEDLINE] 38: Faustman WO, Ringo DL, Lindley SE. Cholesterol and violence: is there a connection?Ann Intern Med. 1998 Oct 15;129(8):669; author reply 669-70. No abstractavailable. PMID: 9786820 [PubMed - indexed for MEDLINE] 39: Goldstein MR. Cholesterol and violence: is there a connection?Ann Intern Med. 1998 Oct 15;129(8):668-9; author reply 669-70. No abstractavailable. PMID: 9786819 [PubMed - indexed for MEDLINE] 40: Nash SD. Cholesterol and violence: is there a connection?Ann Intern Med. 1998 Oct 15;129(8):668; author reply 669-70. No abstractavailable. PMID: 9786818 [PubMed - indexed for MEDLINE] 41: Schlienger JL, Goichot B, Pradignac A. [Cholesterolemia and pathology: update]Rev Med Interne. 1998 Mar;19(3):180-4. Review. French. PMID: 9775138 [PubMed - indexed for MEDLINE] 42: Hibbeln JR, Umhau JC, Linnoila M, George DT, Ragan PW, Shoaf SE, VaughanMR, Rawlings R, Salem N Jr. A replication study of violent and nonviolent subjects: cerebrospinal fluidmetabolites of serotonin and dopamine are predicted by plasma essential fattyacids.Biol Psychiatry. 1998 Aug 15;44(4):243-9. PMID: 9715355 [PubMed - indexed for MEDLINE] 43: Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, George DT, Salem N Jr. Essential fatty acids predict metabolites of serotonin and dopamine incerebrospinal fluid among healthy control subjects, and early- and late-onsetalcoholics.Biol Psychiatry. 1998 Aug 15;44(4):235-42. PMID: 9715354 [PubMed - indexed for MEDLINE] 44: Kaplan JR, Muldoon MF, Manuck SB, Mann JJ. Assessing the observed relationship between low cholesterol andviolence-related mortality. Implications for suicide risk.Ann N Y Acad Sci. 1997 Dec 29;836:57-80. Review. PMID: 9616794 [PubMed - indexed for MEDLINE] 45: Mufti RM, Balon R, Arfken CL. Low cholesterol and violence.Psychiatr Serv. 1998 Feb;49(2):221-4. PMID: 9575009 [PubMed - indexed for MEDLINE] 46: Golomb BA. Cholesterol and violence: is there a connection?Ann Intern Med. 1998 Mar 15;128(6):478-87. Review. PMID: 9499332 [PubMed - indexed for MEDLINE] 47: Boston PF, Dursun SM, Reveley MA. Cholesterol and mental disorder.Br J Psychiatry. 1996 Dec;169(6):682-9. Review. PMID: 8968624 [PubMed - indexed for MEDLINE] 48: Virkkunen M, Eggert M, Rawlings R, Linnoila M. A prospective follow-up study of alcoholic violent offenders and fire setters.Arch Gen Psychiatry. 1996 Jun;53(6):523-9. PMID: 8639035 [PubMed - indexed for MEDLINE] 49: Golomb B. Low cholesterol and violence.Arch Intern Med. 1995 Dec 11-25;155(22):2485. No abstract available. PMID: 7503611 [PubMed - indexed for MEDLINE] 50: Strandberg TE, Salomaa VV, Vanhanen HT, Naukkarinen VA, Sarna SJ, MiettinenTA. Mortality in participants and non-participants of a multifactorial preventionstudy of cardiovascular diseases: a 28 year follow up of the HelsinkiBusinessmen Study.Br Heart J. 1995 Oct;74(4):449-54. PMID: 7488463 [PubMed - indexed for MEDLINE] 51: Strandberg T. Serum cholesterol concentrations in parasuicide. No association between lowcholesterol and violent death.BMJ. 1995 Sep 23;311(7008):807-8. No abstract available. PMID: 7580453 [PubMed - indexed for MEDLINE] 52: Gallerani M, Manfredini R, Caracciolo S, Scapoli C, Molinari S, Fersini C. Serum cholesterol concentrations in parasuicide.BMJ. 1995 Jun 24;310(6995):1632-6. PMID: 7795448 [PubMed - indexed for MEDLINE] 53: Schwandt P, Richter WO, Sonnichsen AC. Lowering high plasma cholesterol levels is not dangerous.Arch Intern Med. 1995 May 8;155(9):985. No abstract available. PMID: 7726707 [PubMed - indexed for MEDLINE] 54: Penttinen J. Hypothesis: low serum cholesterol, suicide, and interleukin-2.Am J Epidemiol. 1995 Apr 15;141(8):716-8. PMID: 7709913 [PubMed - indexed for MEDLINE] 55: Friedman EH. Neurobiology of cholesterol and violent behavior.Arch Intern Med. 1995 Mar 13;155(5):543-4. No abstract available. PMID: 7864712 [PubMed - indexed for MEDLINE] 56: Serjeant ME. Cholesterol and violent behavior.Arch Intern Med. 1995 Mar 13;155(5):544. No abstract available. PMID: 7726951 [PubMed - indexed for MEDLINE] 57: Toshima H, Koga Y, Menotti A, Keys A, Blackburn H, Jacobs DR, SeccarecciaF. The seven countries study in Japan. Twenty-five-year experience incardiovascular and all-causes deaths.Jpn Heart J. 1995 Mar;36(2):179-89. PMID: 7596038 [PubMed - indexed for MEDLINE] 58: Hillbrand M, Spitz RT, Foster HG. Serum cholesterol and aggression in hospitalized male forensic patients.J Behav Med. 1995 Feb;18(1):33-43. PMID: 7595950 [PubMed - indexed for MEDLINE] 59: Richter WO. [Increased autoaggression caused by cholesterol lowering drugs?]Fortschr Med. 1994 Dec 20;112(35-36):507-8. German. No abstract available. PMID: 7843681 [PubMed - indexed for MEDLINE] 60: Paunio M, Heinonen OP, Virtamo J, Klag MJ, Manninen V, Albanes D, ComstockGW. HDL cholesterol and mortality in Finnish men with special reference to alcoholintake.Circulation. 1994 Dec;90(6):2909-18. PMID: 7994838 [PubMed - indexed for MEDLINE] 61: Boston PF, Dursun SM, Reveley MA. Cholesterol and violent death. Other studies exist.BMJ. 1994 Nov 5;309(6963):1228. No abstract available. PMID: 7987161 [PubMed - indexed for MEDLINE] 62: Hughes M. Cholesterol and violent death. Diets, violence, and civilization.BMJ. 1994 Nov 5;309(6963):1228. No abstract available. PMID: 7987160 [PubMed - indexed for MEDLINE] 63: Owens D. Cholesterol and violent death. Clinical importance is questionable.BMJ. 1994 Nov 5;309(6963):1228. No abstract available. PMID: 7987159 [PubMed - indexed for MEDLINE] 64: Kaplan JR, Shively CA, Fontenot MB, Morgan TM, Howell SM, Manuck SB,Muldoon MF, Mann JJ. Demonstration of an association among dietary cholesterol, central serotonergicactivity, and social behavior in monkeys.Psychosom Med. 1994 Nov-Dec;56(6):479-84. PMID: 7532867 [PubMed - indexed for MEDLINE] 65: Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Lonnqvist J, Ehnholm C. Serum cholesterol concentration and mortality from accidents, suicide, andother violent causes.BMJ. 1994 Aug 13;309(6952):445-7. PMID: 7920128 [PubMed - indexed for MEDLINE] 66: Santiago JM, Dalen JE. Cholesterol and violent behavior.Arch Intern Med. 1994 Jun 27;154(12):1317-21. Review. Erratum in: Arch InternMed 1994 Sep 26;154(18):2047. PMID: 8002683 [PubMed - indexed for MEDLINE] 67: Ernst E. Cholesterol and violence: more questions than answers.Br J Hosp Med. 1994 Apr 6-19;51(7):329-30, 332-3. No abstract available. PMID: 8081561 [PubMed - indexed for MEDLINE] 68: Spitz RT, Hillbrand M, Foster HG Jr. Serum cholesterol levels and frequency of aggression.Psychol Rep. 1994 Apr;74(2):622. PMID: 8197299 [PubMed - indexed for MEDLINE] 69: Lewis B, Tikkanen MJ. Low blood total cholesterol and mortality: causality, consequence andconfounders.Am J Cardiol. 1994 Jan 1;73(1):80-5. No abstract available. PMID: 8279383 [PubMed - indexed for MEDLINE] 70: Dursun SM, Reveley MA. Low serum cholesterol and serotonin receptor subtypes.Br J Psychiatry. 1993 Sep;163:417-8. No abstract available. PMID: 8401981 [PubMed - indexed for MEDLINE] 71: Ong HT. Cholesterol reduction therapy: a double-edged knife.Med J Malaysia. 1993 Jun;48(2):107-12. Review. Erratum in: Med J Malaysia 1993Sep;48(3):iv. PMID: 8350783 [PubMed - indexed for MEDLINE] 72: Gray RF, Corrigan FM, Strathdee A, Skinner ER, van Rhijn AG, Horrobin DF. Cholesterol metabolism and violence: a study of individuals convicted ofviolent crimes.Neuroreport. 1993 Jun;4(6):754-6. PMID: 8347820 [PubMed - indexed for MEDLINE] 73: Hawthon K, Cowen P, Owens D, Bond A, Elliott M. Low serum cholesterol and suicide.Br J Psychiatry. 1993 Jun;162:818-25. PMID: 7980726 [PubMed - indexed for MEDLINE] 74: Epstein FH. Low serum cholesterol and death due to accidents, violence, or suicide.Lancet. 1993 May 1;341(8853):1150. No abstract available. PMID: 8097829 [PubMed - indexed for MEDLINE] 75: Schuit AJ, Dekker JM, Schouten EG, Kok FJ. Low serum cholesterol and death due to accidents, violence, or suicide.Lancet. 1993 Mar 27;341(8848):827. No abstract available. Erratum in: Lancet1993 May 1;341(8853):1150. PMID: 8096023 [PubMed - indexed for MEDLINE] 76: Hillbrand M, Foster HG. Serum cholesterol levels and severity of aggression.Psychol Rep. 1993 Feb;72(1):270. No abstract available. PMID: 8451361 [PubMed - indexed for MEDLINE] 77: Kromhout D, Katan MB, Menotti A, Keys A, Bloemberg B. Serum cholesterol and long-term death rates from suicide, accidents, orviolence. Seven Countries Study Group.Lancet. 1992 Aug 1;340(8814):317. No abstract available. PMID: 1353240 [PubMed - indexed for MEDLINE] 78: Ball M, Mann J. Cholesterol lowering--the sense and the sensationalism.N Z Med J. 1992 Jul 22;105(938):283-4. No abstract available. PMID: 1386655 [PubMed - indexed for MEDLINE] 79: Samuel P. Violent death and cholesterol reduction.Lancet. 1992 Jul 4;340(8810):50-1. No abstract available. PMID: 1351622 [PubMed - indexed for MEDLINE] 80: Peer DA, Stoukides CA. Association of low cholesterol with aggression.Ann Pharmacother. 1992 Jun;26(6):785-6. Review. No abstract available. PMID: 1611162 [PubMed - indexed for MEDLINE] 81: Oliver MF. Low serum cholesterol and suicide.Lancet. 1992 May 9;339(8802):1168-9. No abstract available. PMID: 1349387 [PubMed - indexed for MEDLINE] 82: Modest G. Long-term mortality after primary prevention for cardiovascular disease.JAMA. 1992 Apr 22-29;267(16):2184; author reply 2185-6. No abstract available.Erratum in: JAMA 1993 Feb 3;269(5):591. PMID: 1556788 [PubMed - indexed for MEDLINE] 83: Engelberg H. Low serum cholesterol and suicide.Lancet. 1992 Mar 21;339(8795):727-9. PMID: 1347593 [PubMed - indexed for MEDLINE] 84: Rossouw JE, Canner PL, Hulley SB. Deaths from injury, violence, and suicide in secondary prevention trials ofcholesterol lowering.N Engl J Med. 1991 Dec 19;325(25):1813. No abstract available. PMID: 1834942 [PubMed - indexed for MEDLINE] 85: Kaplan JR, Manuck SB, Shively C. The effects of fat and cholesterol on social behavior in monkeys.Psychosom Med. 1991 Nov-Dec;53(6):634-42. PMID: 1758948 [PubMed - indexed for MEDLINE] 86: Pekkanen J, Poikolainen K. [Cholesterol-lowering drugs and violent deaths]Duodecim. 1991;107(14):1145-8. Finnish. No abstract available. PMID: 1670510 [PubMed - indexed for MEDLINE] 87: Wysowski DK, Gross TP. Deaths due to accidents and violence in two recent trials ofcholesterol-lowering drugs.Arch Intern Med. 1990 Oct;150(10):2169-72. PMID: 2222103 [PubMed - indexed for MEDLINE] 88: [No authors listed] Lowering cholesterol concentrations and mortality.BMJ. 1990 Sep 15;301(6751):552-5. No abstract available. PMID: 2271045 [PubMed - indexed for MEDLINE] 89: Wigle DT, Mao Y, Semenciw R, McCann C, Davies JW. Premature deaths in Canada: impact, trends and opportunities for prevention.Can J Public Health. 1990 Sep-Oct;81(5):376-81. Erratum in: Can J Public Health1991 Jan-Feb;82(1):26. PMID: 2253155 [PubMed - indexed for MEDLINE] 90: Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review ofprimary prevention trials.BMJ. 1990 Aug 11;301(6747):309-14. PMID: 2144195 [PubMed - indexed for MEDLINE] 91: Pekkanen J, Nissinen A, Punsar S, Karvonen MJ. Serum cholesterol and risk of accidental or violent death in a 25-yearfollow-up. The Finnish cohorts of the Seven Countries Study.Arch Intern Med. 1989 Jul;149(7):1589-91. PMID: 2742433 [PubMed - indexed for MEDLINE] 92: Kivela SL, Nissinen A, Ketola A, Punsar S, Puska P, Karvonen M. Alcohol consumption and mortality in aging or aged Finnish men.J Clin Epidemiol. 1989;42(1):61-8. Erratum in: J Clin Epidemiol 1989;42(7):701. PMID: 2913188 [PubMed - indexed for MEDLINE] 93: Farchi G, Menotti A, Conti S. Coronary risk factors and survival probability from coronary and other causesof death.Am J Epidemiol. 1987 Sep;126(3):400-8. PMID: 3618576 [PubMed - indexed for MEDLINE] 94: Virkkunen ME, Horrobin DF, Jenkins DK, Manku MS. Plasma phospholipid essential fatty acids and prostaglandins in alcoholic,habitually violent, and impulsive offenders.Biol Psychiatry. 1987 Sep;22(9):1087-96. PMID: 2958095 [PubMed - indexed for MEDLINE] 95: Gualandri V, Franceschini G, Sirtori CR, Gianfranceschi G, Orsini GB,Cerrone A, Menotti A. AIMilano apoprotein identification of the complete kindred and evidence of adominant genetic transmission.Am J Hum Genet. 1985 Nov;37(6):1083-97. PMID: 3936350 [PubMed - indexed for MEDLINE] 96: Virkkunen M. Lipid Research Clinics Coronary Primary Prevention Trial results.JAMA. 1985 Feb 1;253(5):635-6. No abstract available. PMID: 3968799 [PubMed - indexed for MEDLINE] 97: Virkkunen M, Penttinen H. Serum cholesterol in aggressive conduct disorder: a preliminary study.Biol Psychiatry. 1984 Mar;19(3):435-9. No abstract available. PMID: 6722234 [PubMed - indexed for MEDLINE] 98: Virkkunen M. Serum cholesterol levels in homicidal offenders. A low cholesterol level isconnected with a habitually violent tendency under the influence of alcohol.Neuropsychobiology. 1983;10(2-3):65-9. PMID: 6674827 [PubMed - indexed for MEDLINE] 99: [No authors listed] W.H.O. cooperative trial on primary prevention of ischaemic heart disease usingclofibrate to lower serum cholesterol: mortality follow-up. Report of theCommittee of Principal Investigators.Lancet. 1980 Aug 23;2(8191):379-85. PMID: 6105515 [PubMed - indexed for MEDLINE] 100: Kozararevic D, McGee D, Vojvodic N, Racic Z, Dawber T, Gordon T, Zukel W. Frequency of alcohol consumption and morbidity and mortality: The YugoslaviaCardiovascular Disease Study.Lancet. 1980 Mar 22;1(8169):613-6. PMID: 6102625 [PubMed - indexed for MEDLINE] 101: Carruthers M, Taggart P. Vagotonicity of violence: biochemical and cardiac responses to violent filmsand television programmes.Br Med J. 1973 Aug 18;3(5876):384-9. No abstract available. PMID: 4730188 [PubMed - indexed for MEDLINE] 102: Mushin A, Morgan G. Ocular injury in the battered baby syndrome. Report of two cases.Br J Ophthalmol. 1971 May;55(5):343-7. No abstract available. PMID: 5579167 [PubMed - indexed for MEDLINE]
> Reading the responses to my question, I have another question. Will > dementia caused by a statin drug respond to a medicine for Alzheimers? [quoted text clipped - 3 lines] > we were all miserable. Once she started back on her meds, she was her > usual perky (but still confused) self. Karen - 23 Apr 2005 02:10 GMT From what I've read, excess cholesterol may be implicated in Alzheimer's but statins are known to cause Alzheimer's like symptoms in some people. Others have no problems with statins. Why seems to be a mystery they haven't yet solved. Seems there isn't nearly as much money available to research the adverse effects of drugs versus funding for the benefits (IMO).
The Alzheimer's like symptoms are one of those things doctors don't like to acknowledge. Like the link between depression and statins. Seems some people (particularly males) need cholesterol to keep their seratonin levels in balance. A friend of mine finally said he'd rather die young after several cycles of statins and anti-depressants (and he follows a healthy lifestyle).
Karen
> There is some evidence that statins LOWER the risk of Alzheimer's. > [quoted text clipped - 16 lines] > > Alan Karen - 23 Apr 2005 02:37 GMT On re-reading this, I have to point out that blockage of blood to the brain can also cause dementia and memory loss.
Karen
> From what I've read, excess cholesterol may be implicated in Alzheimer's but > statins are known to cause Alzheimer's like symptoms in some people. Others [quoted text clipped - 31 lines] > > > > Alan Sharon Hope - 23 Apr 2005 02:17 GMT Incorrect. There is absolutely NO EVIDENCE that statins lower the risk of Alzheimers.
What you have seen is a plethora of published articles speculating on the topic. The studies that have been published (vs the Position Papers and Hype) all have come in as negative or inconclusive findings.
Prior to some results, one team of participating doctors published on the difficulty of even running the study, because so many of the statin group 'washed out' of the study because of adverse effects.
The timing for of these speculative articles with titles like, "Could statins prevent AZ?" is very suspicious, as it looks simply like marketing spin, given it came on the heels of some popular press articles on devastating, debilitating, disabling memory loss, amnesia, aphasia and other cognitive damage directly attributable to statins.
See, for example, the reprint of the Smart Money Magazine article, "Lipitor, Thief of Memory." I have first-hand knowledge that the information in the story is correct. http://www.n3inc.com/SmartMoneyReprint_103003Web.pdf
See also Dr. Graveline's two books: See also Dr. Graveline's website for his book "Lipitor, Thief of Memory," and his new book, "Statin Drugs Side Effects." http://www.spacedoc.net/
Then do the search on Pub Med and READ the abstracts. NO EVIDENCE that statins lower the risk of Alzheimers. Then do the search on Cognitive and read the studies that show statins CAUSE memory loss.
>> Are there any scientific studies that link cholesterol drugs (Lipitor, >> Zocor, ect) as a cause of Alzheimers? My mother is taking Lipitor. My [quoted text clipped - 30 lines] > > Alan outrider@despammed.com - 23 Apr 2005 05:23 GMT > Are there any scientific studies that link cholesterol drugs (Lipitor, > Zocor, ect) as a cause of Alzheimers? My mother is taking Lipitor. My [quoted text clipped - 9 lines] > > Any help would be appreciated! Your mother's dementia may well be caused by Lipitor (or any statin). Mine was. I have recovered a great deal, but still not enough to return to a career as a reporter, journalist, writer and editor.
Here is a television story about someone who experienced what you mother may be experiencing. Further down in this thread, read Sharon Hope's post for clinical studies and the name of a National Institutes of Health funded researcher in statin induced dementia, memory loss, aphasia, and other toxic cognitive and physical damage.
http://www.cbsnews.com/stories/2004/05/24/eveningnews/main619351.shtml
Zee no cardiovascular disease, total cholesterol 9.7 still recovering from serious statin injury
|
|
|